Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results

ABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This...

Full description

Bibliographic Details
Main Author: Ertan,Elif (author)
Other Authors: Doğan,Mustafa (author), Polat,Onur (author), Efe,Neriman (author), Akdoğan,Müberra (author), İnan,Sibel (author), Duman,Reşat (author), Duman,Rahmi (author)
Format: article
Language:eng
Published: 2021
Subjects:
Macular degeneration
Ranibizumab/therapeutic use
Angiogenesis inhibitors/therapeutic use
Intravitreal injections
Retina/pathology
Visual acuity
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225
Country:Brazil
Oai:oai:scielo:S0004-27492021000300225

Internet

http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492021000300225

Similar Items